Grupo Medifarma, S. A. de C. V.   Report issue

For profit Phase 3
Founded: Jiutepec Mexico (1964)

Organization Overview

First Clinical Trial
2015
NCT02496182
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

pirfenidone (esbriet) (3 trials)

triamcinolone (kenalog) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 3)

Alveolitis, Extrinsic Allergic (Phase 3)

Diabetic Nephropathies (Phase 3)

Hypersensitivity (Phase 3)

Keloid (Phase 3)

Kidney Diseases (Phase 3)

Pneumonia (Phase 3)

Pulmonary Fibrosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2